10-Q · latest 10
What BD's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 12 signals
BDX spins off Biosciences & Diagnostic Solutions in Reverse Morris Trust deal with Waters Corp.
Becton Dickinson is executing a complex spin-off of its Biosciences and Diagnostic Solutions businesses and combining them with Waters Corporation.
Waters Corporation
BDX manages large-scale replacement of Alaris Infusion Systems under FDA Consent Decree.
The company's U.S. infusion pump business is operating under an FDA Consent Decree, forcing a large-scale replacement and return-to-market for its BD Alaris™ Infusion Systems.
BDX operating under FDA Consent Decree for Alaris™ infusion pump business
The company's U.S. infusion pump business is subject to an FDA Consent Decree that could lead to forced production halts, recalls, or significant fines for non-compliance.
BDX completes spin-off and merger of Biosciences/Diagnostics units with Waters Corporation.
Waters Corporation
BDX identifies AI as a key strategic area for development and deployment.
Becton Dickinson is actively developing and deploying Artificial Intelligence in its products and business operations, while also citing AI use by competitors as a significant risk.
AIartificial intelligence
Facing multiple large-scale lawsuits over hernia, port, and filter products
BDX is defending against significant pending litigation, including potential class actions, related to several product lines such as hernia implants and implantable ports.
Supply chain at risk due to increased regulation of ethylene oxide sterilization
Increased regulatory focus on the use and emission of ethylene oxide poses a significant threat to BDX's product sterilization processes, potentially disrupting manufacturing, increasing costs, and impacting product availability for both the company and its third-party providers.
BDX flags risk of losing ground to competitors leveraging Artificial Intelligence
The company explicitly identifies the use of emerging technologies like AI by competitors as a key threat.
AIartificial intelligence
Managing tax implications of Biosciences spin-off and combination with Waters Corp.
BDX is navigating complex tax risks following the major strategic restructuring involving the spin-off of its Biosciences and Diagnostic Solutions businesses and their subsequent combination with Waters Corporation.
Waters Corporation
Facing margin pressure from low-cost manufacturers and government tenders
BDX's profitability is being challenged by both low-cost manufacturing competitors and government cost-containment measures, such as China's volume-based procurement and competitive bidding programs, forcing the company to find new efficiencies or risk margin erosion.
Showing 10 of 36 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
BD earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Q3 revenue hits $5B, up 4.4%, with 90% of portfolio in high single-digit growthDelivered strong Q3 results with revenue of $5 billion, a 4.4% increase, exceeding expectations. Performance was broad-based, with over 90% of the portfolio delivering high single-digit growth. Adjusted operating margin was 24.9% and adjusted EPS was $3.23, up 4.9%, driven by momentum in key growth platforms and strong operational execution. | |
| Strong Q3 performance with $5B revenue, up 4.4%Delivered strong Q3 results ahead of expectations, with revenue reaching $5 billion, a 4.4% year-over-year increase. This performance was broad-based, with over 90% of the portfolio achieving high single-digit growth, reflecting strong commercial momentum and operational execution in the first full quarter as 'New BD'. | |
| Investing in standardized digital platform with AI for supply chainAs part of its 'Deliver' strategic pillar, the company has begun investing in a standardized digital platform to deploy AI across its end-to-end supply chain. This initiative is expected to create a meaningful runway for future productivity and service improvements, building on the 8% gross productivity already achieved in plants this quarter. | |
| Secured ~100 agreements for GLP-1 drug delivery programsThe BioPharma Systems business is seeing significant momentum from the biologics market, particularly GLP-1s, growing in the mid-teens excluding vaccines. The company has signed approximately 100 agreements for novel and biosimilar GLP-1 programs and announced a new collaboration with EMS in Brazil to launch a semaglutide therapy using its Vystra injection pen. | |
| Gaining share in specimen management from competitor supply issuesThe specimen management business delivered high single-digit growth, with U.S. growth at 14%, driven by share gains in the BD Vacutainer portfolio. This was enabled by improved supply and the ability to capture incremental demand as customers work through back orders from unnamed competitors. | |
| Known headwinds in Alaris and China vaccines impacting growthGrowth is being partially offset by known dynamics in less than 10% of the portfolio. These include a difficult prior year comparison for the Alaris platform and continued pressure on vaccine-related products in China. The Alaris headwind is expected to increase from 100 basis points this year to 200 basis points in fiscal 2027. |
Signal API · MCP
Track BD with the Signal API
One POST /v1/companies/enrich call with bd.com returns BD 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bd.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about BD 10-Q
When did BD file its latest 10-Q?
What did BD disclose in its latest 10-Q?
What did BD say on its recent earnings calls?
Where can I read BD's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .